T1	Participants 376 519	We assessed genome-wide expression of 300 pretreatment specimens from a subset of 552 patients in REACH, a study of FC or R-FC in relapsed CLL.
T2	Participants 520 648	An independent test set was derived from 282 pretreatment specimens from CLL8, a study of FC or R-FC in treatment-naÃ¯ve patients
